The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer
Open accessAbstract
Many human cancers exhibit elevated prostaglandin (PG) levels due to upregulation of cyclooxygenase-2 (COX-2), a key enzyme in eicosanoid biosynthesis. COX-2 over-expression has been observed in about 40% of cases of invasive breast carcinoma and at a higher frequency in preinvasive ductal carcinoma in situ tumors, Extensive pharmacologic and genetic evidence implicates COX enzymes in neoplasia. Epidemiologic analyses demonstrate a protective effect of COX-inhibiting nonsteroidal anti-inflammatory drugs with respect to human cancer. Complementary experimental studies have established that both conventional nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors suppress mammary tumor formation in rodent breast cancer models. Furthermore, knocking out Cox-2 reduces mammary tumorigenesis and angiogenesis, and, conversely, transgenic COX-2 over-expression induces tumor formation. The utility of COX/PG signaling as a target for chemoprevention has been established by randomized controlled clinical trials. However, these studies also identified increased cardiovascular risk associated with use of selective COX-2 inhibitors. Thus, current efforts are directed toward identifying safer approaches to antagonizing COX/PG signaling for cancer prevention and treatment, with a particular focus on PGE2 regulation and signaling, because PGE2 is a key pro-tumorigenic prostanoid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Prostanoid Receptors: Structures, Properties, and Functions
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1193 · Cited by 2,412
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., & Taketo, M. M. (1996) · Cell · doi:10.1016/s0092-8674(00)81988-1 · Cited by 2,366
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
Herschman, H. R. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00194-8 · Cited by 1,197
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., Tang, J., Rosenstein, R. B., Wittes, J., Corle, D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061355 · Cited by 1,048
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Celecoxib for the Prevention of Colorectal Adenomatous Polyps
Arber, N., Eagle, C. J., Spicak, J., Rácz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M. J., Gerletti, P., Tang, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061652 · Cited by 975
COX-2 is expressed in human pulmonary, colonic, and mammary tumors
Soslow, R. A., Dannenberg, A. J., Rush, D., Woerner, B. M., Khan, K. N., Masferrer, J., & Koki, A. T. (2000) · Cancer · doi:10.1002/1097-0142(20001215)89:12<2637::aid-cncr17>3.0.co;2-b · Cited by 862
Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice
Liu, C. H., Chang, S.-H., Narko, K., Trifan, O. C., Wu, M.-T., Smith, E., Haudenschild, C., Lane, T. F., & Hla, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010787200 · Cited by 807
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ristimaki, A. P., Sivula, A., Lundin, J. E., Lundin, M., Salminen, T. M., Haglund, C. H., Joensuu, H., & Isola, J. J. (2002) · PubMed · Cited by 780
Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study
Schreinemachers, D. M., & Everson, R. B. (1994) · Epidemiology · doi:10.1097/00001648-199403000-00003 · Cited by 736
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Harris, R. E., Alshafie, G. A., Abou‐Issa, H., & Seibert, K. (2000) · PubMed · Cited by 540
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer
Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., & Subbaramaiah, K. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00488-0 · Cited by 508
Self-citationGenetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.
Chulada, P. C., Thompson, M. B., Mahler, J. F., Doyle, C. M., Gaul, B. W., Lee, C., Tiano, H. F., Morham, S. G., Smithies, O., & Langenbach, R. J. (2000) · PubMed · Cited by 496
COX-2: A Molecular Target for Colorectal Cancer Prevention
Brown, J. R., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.051 · Cited by 444
Siegel, P. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2149 · Cited by 442
Zhao, Y. D., Agarwal, V. R., Mendelson, C. R., & Simpson, E. R. (1996) · Endocrinology · doi:10.1210/en.137.12.5739 · Cited by 434
A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas
Baron, J. A., Sandler, R. S., Bresalier, R. S., Quan, H., Riddell, R., Lanas, A., Bolognese, J. A., Oxenius, B., Horgan, K., Loftus, S., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.079 · Cited by 433
Harris, R. E., Chlebowski, R. T., Jackson, R. D., Frid, D. J., Ascenseo, J. L., Anderson, G. L., Loar, A., Rodabough, R. J., White, E., & McTiernan, A. (2003) · PubMed · Cited by 411
Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors
Grösch, S., Maier, T. J., Schiffmann, S., & Geisslinger, G. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj206 · Cited by 400
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half, E., Tang, X., Gwyn, K. M., Şahin, A. A., Wathen, K., & Sinicrope, F. A. (2002) · PubMed · Cited by 384
Chang, S.-H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., Lane, T. F., & Hla, T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2535911100 · Cited by 361
Nonsteroidal Antiinflammatory Drugs and Breast Cancer
Harris, R. E., Namboodiri, K. K., & Farrar, W. B. (1996) · Epidemiology · doi:10.1097/00001648-199603000-00017 · Cited by 345
Tiano, H. F., Loftin, C. D., Akunda, J., Lee, C. A., Spalding, J. W., Sessoms, A. R., Dunson, D. B., Rogan, E. G., Morham, S. G., Smart, R. C., et al. (2002) · PubMed · Cited by 344
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function
Cheng, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27540 · Cited by 339
Seno, H., Oshima, M., Ishikawa, T., Oshima, H., Takaku, K., Chiba, T., Narumiya, S., & Taketo, M. M. (2002) · PubMed · Cited by 327
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Howe, L. R., Subbaramaiah, K., Brown, A. M., & Dannenberg, A. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080097 · Cited by 322
Self-citationCyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer
Subbaramaiah, K., Norton, L., Gerald, W., & Dannenberg, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111415200 · Cited by 317
15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Colorectal Cancer
Backlund, M. G., Mann, J. R., Holla, V. R., Buchanan, F. G., Tai, H.-H., Musiek, E. S., Milne, G. L., Katkuri, S., & DuBois, R. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411221200 · Cited by 301
Costa, C., Soares, R., Reis-Filho, J. S., Leitao, D., Amendoeira, I., & Schmitt, F. C. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.6.429 · Cited by 275
Breast cancer and NSAID use: a meta-analysis
Khuder, S. A., & Mutgi, A. B. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1709 · Cited by 273
Terry, M. B. (2004) · JAMA · doi:10.1001/jama.291.20.2433 · Cited by 271
Corpet, D. E., & Pierre, F. H. F. (2003) · PubMed · Cited by 264
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis
Myung, S.-J., Rerko, R. M., Yan, M., Platzer, P., Guda, K., Dotson, A., Lawrence, E., Dannenberg, A. J., Lovgren, A. K., Luo, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603235103 · Cited by 264
Agarwal, V. R. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.3843 · Cited by 258
Yan, M., Rerko, R. M., Platzer, P., Dawson, D., Willis, J., Tong, M., Lawrence, E., Lutterbaugh, J., Lu, S., Willson, J. K. V., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406142101 · Cited by 243
Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens
Brueggemeier, R. W., Quinn, A. L., Parrett, M. L., Joarder, F. S., Harris, R. E., & Robertson, F. M. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00050-6 · Cited by 238
Regulation of Cyclooxygenase-2 pathway by HER2 receptor
Vadlamudi, R., Mandal, M., Adam, L., Steinbach, G., Mendelsohn, J., & Kumar, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202307 · Cited by 222
Howe, L. R., Subbaramaiah, K., Patel, J. A., Masferrer, J. L., Deora, A., Hudis, C. A., Thaler, H. T., Muller, W. J., Du, B., Brown, A. M. C., et al. (2002) · PubMed · Cited by 219
Self-citationReduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors
Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-27 · Cited by 214
15-Hydroxyprostaglandin Dehydrogenase Is a Tumor Suppressor of Human Breast Cancer
Wolf, I., O'Kelly, J., Rubinek, T., Tong, M., Nguyen, A., Lin, B. T., Tai, H.-H., Karlan, B. Y., & Koeffler, H. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4368 · Cited by 206
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ
Boland, G. P., Butt, I. S., Prasad, R., Knox, W. F., & Bundred, N. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601534 · Cited by 197
Sharpe, C. R., Collet, J.-P., McNutt, M., Belzile, E., Boivin, J.-F., & Hanley, J. A. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1119 · Cited by 187
Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer.
Yoshimatsu, K., Altorki, N. K., Golijanin, D., Zhang, F., Jakobsson, P. ‐., Dannenberg, A. J., & Subbaramaiah, K. (2001) · PubMed · Cited by 182
Howe, L. R., Chang, S.-H., Tolle, K. C., Dillon, R., Young, L. J. T., Cardiff, R. D., Newman, R. A., Yang, P., Thaler, H. T., Muller, W. J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1524 · Cited by 165
Self-citationDing, Y. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh277 · Cited by 159
Cyclooxygenase Inhibitors Suppress Aromatase Expression and Activity in Breast Cancer Cells
Díaz‐Cruz, E. S., Shapiro, C. L., & Brueggemeier, R. W. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2029 · Cited by 156
PEA3 Is Up-regulated in Response to Wnt1 and Activates the Expression of Cyclooxygenase-2
Howe, L. R., Crawford, H. C., Subbaramaiah, K., Hassell, J. A., Dannenberg, A. J., & Brown, A. M. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010692200 · Cited by 151
Self-citationAromatase and COX-2 expression in human breast cancers
Brodie, A. M., Lü, Q., Long, B. J., Fulton, A. M., Chen, T., Macpherson, N. A., DeJong, P. C., Blankenstein, M. A., Nortier, J. W. R., Slee, P. H. T. J., et al. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00131-5 · Cited by 150
Crawford, Y., Gauthier, M. L., Joubel, A., Mantei, K., Kozakiewicz, K., Afshari, C. A., & Tlsty, T. D. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00023-6 · Cited by 148
Initial Screening for Carcinogenicity of Commonly Used Drugs23
FRIEDMAN, G. D., & Ury, H. K. (1980) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/65.4.723 · Cited by 148
Targeting Prostaglandin E EP Receptors to Inhibit Metastasis
Fulton, A. M., Ma, X., & Kundu, N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2067 · Cited by 141
Nakatsugi, S., Ohta, T., Kawamori, T., Mutoh, M., Tanigawa, T., Watanabe, K., Sugie, S., Sugimura, T., & Wakabayashi, K. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb01030.x · Cited by 121
Reddy, B. S. (2004) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20026 · Cited by 113
Spizzo, G., Gastl, G. A., Wolf, D. G. F., Gunsilius, E., Steurer, M., Fong, D., Amberger, A., Margreiter, R., & Obrist, P. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600741 · Cited by 109
Mann, J. R., Backlund, M. G., Buchanan, F. G., Daikoku, T., Holla, V. R., Rosenberg, D. W., Dey, S. K., & DuBois, R. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1787 · Cited by 109
Subbaramaiah, K., Howe, L. R., Port, E. R., Brogi, E., Fishman, J., Liu, C. H., Hla, T., Hudis, C. A., & Dannenberg, A. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4076 · Cited by 97
Self-citationAssociation between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer
Rahme, E., Ghosn, J., Dasgupta, K., Rajan, R., & Hudson, M. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-159 · Cited by 96
Shim, V., Gauthier, M. L., Sudilovsky, D., Mantei, K., Chew, K., Moore, D. H., Cha, I., Tlsty, T. D., & Esserman, L. J. (2003) · PubMed · Cited by 93
Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.
Takeda, H., Sonoshita, M., Oshima, H., Sugihara, K.-I., Chulada, P. C., Langenbach, R. J., Oshima, M., & Taketo, M. M. (2003) · PubMed · Cited by 92
Microsomal prostaglandin E2 synthase‐1 in breast cancer: a potential target for therapy
Mehrotra, S., Morimiya, A., Agarwal, B., Konger, R. L., & Badve, S. (2005) · The Journal of Pathology · doi:10.1002/path.1907 · Cited by 87
Lanza‐Jacoby, S., Miller, S., Flynn, J. T., Gallatig, K., Daskalakis, C., Masferrer, J. L., Zweifel, B. S., Sembhi, H., & Russo, I. H. (2003) · PubMed · Cited by 81
Role of COX-Independent Targets of NSAIDs and Related Compounds in Cancer Prevention and Treatment
Soh, J. W., & Weinstein, B. (2003) · KARGER eBooks · doi:10.1159/000071377 · Cited by 76
Breast tumor aromatase: functional role and transcriptional regulation.
Chen, S., Zhou, D., Okubo, T., Kao, Y., & Yang, C. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060149 · Cited by 70
Prosperi, J. R., & Robertson, F. M. (2006) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2006.07.003 · Cited by 63
Hamid, R., Singh, J., Reddy, B. S., & Cohen, L. A. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.3.523 · Cited by 58
Expression of Cyclooxygenase-1 and -2 in Human Breast Cancer
Yoshimura, N., Sano, H., Okamoto, M., Akioka, K., Ushigome, H., KADOTANI, Y., Yoshimura, R., Nobori, S., Higuchi, A., Ohmori, Y., et al. (2003) · Surgery Today · doi:10.1007/s00595-003-2606-3 · Cited by 45
Chemoprevention of mammary carcinogenesis in female rats by rofecoxib
Kubatka, P., Ahlers, I., Ahlersová, E., Adámeková, E., Luk, P., Bojková, B., & Marková, M. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.08.006 · Cited by 37
Cited by
Kalyane, D., Raval, N., Maheshwari, R., Tambe, V., Kalia, K., & Tekade, R. K. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.01.066 · Cited by 849
Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin D
Krishnan, A. V., & Feldman, D. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100611 · Cited by 470
Lyons, T. R., O'Brien, J., Borges, V. F., Conklin, M. W., Keely, P. J., Eliceiri, K. W., Marusyk, A., Tan, A.-C., & Schedin, P. (2011) · Nature Medicine · doi:10.1038/nm.2416 · Cited by 380
Regulation of inflammation in cancer by eicosanoids
Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2011.08.004 · Cited by 303
Portrait of inflammatory response to ionizing radiation treatment
Di Maggio, F. M., Minafra, L., Forte, G. I., Cammarata, F. P., Lio, D., Messa, C., Gilardi, M. C., & Bravatà, V. (2015) · Journal of Inflammation · doi:10.1186/s12950-015-0058-3 · Cited by 286
Metadata
- Authors
- Howe, L. R.
- Venue
- Breast Cancer Research
- Published
- 2007-07-16
- Volume
- 9
- Issue
- 4
- Pages
- 210-210
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2070732038
- Cited by
- 293
- References
- 72
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.